Anaphylaxis is a severe allergic reaction to venom, food, or medication. Mostly it is caused by a bee sting or eating foods that are known to cause allergies, such as peanuts or tree nuts. Some of the common causes of anaphylaxis include medication, peanuts, tree nuts, insect stings, fish, shellfish, and milk. Other causes may include exercise and latex.
The primary drug treatments for acute anaphylactic reactions are epinephrine and H1 antihistamines. As per the 2013 World Allergy Association update, 2015 Joint Task Force anaphylaxis update, and 2010 NIAID guidelines, epinephrine is the drug of choice for life-threatening reactions.
Download free sample @ https://www.datamintelligence.com/download-sample/anaphylaxis-treatment-market
The global anaphylaxis treatment Market growth is driven by several factors such growing prevalence of allergies and their awareness among customers, and increasing advancement in the product with cost-effective solutions.
Growing cases of anaphylaxis and rising demand for self-administered drugs are driving the market growth.
The rise in patient pool suffering from allergies globally is a major factor driving the anaphylaxis treatment market. In the US and the UK, the incidence of anaphylaxis is 40–500 per million persons, mortality is estimated at 0.63–0.76 per million. In the US, up to 5% population suffers from this condition. Clinical databases such as PubMed have captured the growing prevalence of anaphylaxis.
As per a journal published on NCBI (National Center for Biotechnology Information) in 2017, up to 5% of the U.S. population suffered from the anaphylaxis condition. In addition, around 1% of total hospitalizations and 0.1% of emergency attendances for anaphylaxis would have fatal outcomes. Drugs are a major cause of fatal anaphylaxis in various countries, such as Australia, New Zealand, the U.K., Brazil, and the U.S. As per a journal published on NCBI, in the year 2018, the lifetime prevalence of anaphylaxis is estimated to be 0.05% – 2% in the U.S., and approx. 3% in Europe. Overall, the fatality of anaphylaxis conditions is relatively low across the globe.
Therefore, the growing incidence of anaphylaxis is likely to increase the high uptake of the anaphylaxis treatment market.
By Drug Class
l Adrenergic Agonists
l H2 Receptor Antagonists
By Route of Administration
By Distribution Channel
l Hospital Pharmacies
l Retail Pharmacies
l Online Pharmacies
Some of the major players in the global anaphylaxis treatment market include ALK-Abelló A/S, Amneal Pharmaceuticals Inc, Adamis Pharmaceuticals Corporation, Kaleo Inc, Mylan N.V, Novartis International AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., among others. The market players are involved in developing cost-effective and robust solutions to gain market share.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the anaphylaxis treatment market globally. For instance,
Teva Pharmaceutical Industries Ltd has developed an EpiPen which is a generic version of EpiPen Jr and approved by the FDA in August 2019. The pen is developed using VIBEX device by Antares Pharma to prevent and provide aid against life-threatening, allergic emergencies including anaphylaxis or any allergic history in genes of the patient. The dose of the EpiPen depends on the weight and fitness of the patient or as prescribed by the medical practitioners.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States